Smith & Nephew (SN) - Turning over that new leaf

06:54 EDT 28 Sep 2018 | Edison Investment Research

Edison Investment Research - Pharmaceutical & healthcare - Smith & Nephew: We had the opportunity to join Smith & Nephew’s (S&N) recent institutional investor roadshow and hear about the introspection that has emerged following the appointment of its new CEO. While endorsing its strategy as a portfolio medical device company, two strategic reviews have identified areas which, when the detail is announced at the Q3 and FY18 results, will enable investors to track S&N’s target of returning to market growth rates.
ISIN: GB0009223206

Original Article: Smith & Nephew (SN) - Turning over that new leaf


More From BioPortfolio on "Smith & Nephew (SN) - Turning over that new leaf"

Quick Search


Relevant Topics

Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...

Medical Devices
The role of medical devices in healthcare is essential.  The diversity and innovativeness of this sector contribute significantly to enhance the quality and efficacy of healthcare.  Covering a wide range of products, from simple bandages to the...